

# Zaltidine

**Catalog No: tcsc1392**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

85604-00-8

**Formula:**

$C_8H_{10}N_6S$

**Pathway:**

Immunology/Inflammation;GPCR/G Protein

**Target:**

Histamine Receptor;Histamine Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

CP-57361

**Observed Molecular Weight:**

222.27

## Product Description


Zaltidine(CP-57361) is a H<sub>2</sub>-receptor antagonist, which has the antisecretory action.

IC<sub>50</sub> Value:

Target: H<sub>2</sub> receptor

in vitro:

in vivo: In eight healthy male volunteers single oral doses of 5 mg, 25 mg and 100 mg produced dose-related inhibition of basal and pentagastrin-stimulated acid output (M.A.O.) with an estimated ID<sub>50</sub> of 40 mg for the latter. In eight subjects with duodenal ulceration single 100 mg and 200 mg doses produced 85% and 97% inhibition of M.A.O. at peak (3 h post-dose) and 20% and 23% inhibition at 24 h, respectively; inhibition of basal acid output was 97% at 3 h and 50% at 24 h with both doses [1]. One hundred and thirty-five patients were randomly allocated to 4 weeks' treatment with either 150 mg zaltidine once daily or placebo. Fifty-nine were treated for a full 4 weeks with zaltidine before the trial was stopped. Healing rates after 4 weeks of zaltidine and placebo were 86% and 19%, respectively (p less than 0.001) [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!